- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals
Aaron Gerds, MD, MS, explores myelofibrosis risk assessment, treatment goals, and therapeutic strategies, including JAK (Janus kinase inhibitors) inhibitors and transplant considerations.
EP: 1.Myelofibrosis: Characteristics and Subtypes
EP: 2.NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
EP: 3.Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life
EP: 4.Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals
EP: 5.NCCN Guidelines 2023: Updates in Myelofibrosis Management
EP: 6.NCCN Guidelines: Categories and Recommendations in Myelofibrosis
EP: 7.Integrating Momelotinib: NCCN Guidelines and Drug Comparison
EP: 8.Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations
EP: 9.Future of Myelofibrosis: Anticipated Data and Emerging Therapies
This is a video synopsis/summary of a Guidelines featuring Aaron Gerds, MD, MS.
Gerds discusses risk assessment in myelofibrosis and its critical role in treatment decisions. He emphasizes the significance of understanding prognosis to determine appropriate interventions. The Dynamic International Prognostic Scoring System is highlighted as a widely used prognostic model, considering factors like molecular data and cytogenetics. Gerds introduces the Merit-Based Incentive Payment System score for molecular data evaluation and the Myelofibrosis Secondary to PV and ET – Prognostic Model (MYSEC-PM) for patients transitioning from essential thrombocythemia or polycythemia vera to myelofibrosis. Prognosis aids in referrals for stem cell transplant and influences participation in clinical trials based on disease risk categories. Moving to treatment goals, Gerds underscores the importance of addressing symptoms and splenomegaly. JAK inhibitors, including ruxolitinib, fedratinib, pacritinib, and momelotinib, focus on improving patients' quality of life. The discussion provides insights into the nuanced approach to MF treatment, considering individual patient characteristics and disease risk levels.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma
November 26th 2024In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.
Read More
